SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

Share Price is delayed by 15 minutes
Get Live Data
73.50    0.50 (0.68%)
Bid:
72.00
Ask:
75.00
Spread: 3.00 (4.167%)
Market Cap: £306.68m
BSV Live PriceLast checked at - London Stock Exchange

Intraday Br.smaller Cos. Share Chart

Interim Management Statement

12 Sep 2025 07:00

RNS Number : 0239Z
British Smaller Companies VCT PLC
12 September 2025
 

British Smaller Companies VCT plc

Interim Management Statement for the quarter ended 30 June 2025

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 30 June 2025. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 30 June 2025 the Company's Net Asset Value (NAV) per share increased by 0.80 pence, a 1.0 per cent increase on the opening NAV per share. At 30 June 2025 the NAV per ordinary share totalled 81.35 pence. 

The Company's Total Return at 30 June 2025 was up 0.80 pence, to 265.50 pence per ordinary share.

During the quarter, the Company invested £2.4 million into new investment S4labour; and invested a further £0.6 million into existing portfolio companies Force24 and Relative Insight. Subsequent to the quarter end, the Company invested £1.8 million into new portfolio company DynaRisk and £3.9 million into three existing portfolio companies, AutomatePro, Fuuse and Panintelligence. This takes the total amount invested so far this year to £8.7 million.

Following the period end, the sale of the trade and liabilities of Wooshii was completed. No proceeds were received on exit, in line with its minimal carrying value at the period end.

The final allotment of the Company's 2024/25 fundraise took place on the first day of the quarter, with £29.6 million allotted on 1 April 2025.

Performance

The table below sets out movements in key metrics for the Company. 

 

 

31 March 2025

Increase in Value

Shares issued

Buyback of shares

Movement

In Period

30 June 2025

Net Assets (£m)

257.1

2.9

29.6

(1.2)

31.3

288.4

NAV per share (PPS)

80.55

0.80

-

-

0.80

81.35

Cumulative dividends paid (PPS)

184.15

-

-

-

-

184.15

Total Return (PPS)

264.70

0.80

-

-

0.80

265.50

Shares in issue

319,178,657

-

36,799,582

(1,495,509)

35,304,073

354,482,730

Cumulative dividends paid at 30 June 2025 were 184.15 pence per ordinary share (31 March 2025: 184.15 pence per ordinary share). Following the payment of the interim dividend of 2.00 pence per ordinary share on 25 July 2025, cumulative dividends paid are now 186.15 pence per ordinary share.

The movements in NAV and NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 31 March 2025

257.1

80.55

Increase in portfolio value

2.7

0.75

Net operating income

0.2

0.05

2.9

0.80

Issue/buy-back of shares

28.4

-

Total Return in the period

31.3

0.80

NAV at 30 June 2025

 

288.4

 

81.35

 

Dividends and shares in issue

On 1 April 2025 the Company issued 36,799,582 shares in relation to the second and final allotment from its 2024/25 fundraising.

Under its standing buyback authority, on 23 June 2025 the Company purchased 1,495,509 shares at 77.02 pence per share at a cost of £1.2 million. These shares are held in treasury. 

Post-period end, on 25 July 2025, a dividend of 2.00 pence per ordinary share for the year ending 31 March 2026 was paid, resulting in a corresponding reduction in the Company's NAV per ordinary share, adjusting the last reported NAV to 79.35 pence per ordinary share. Cumulative dividends paid are now 186.15 pence per ordinary share.

On 25 July 2025 the Company also issued 1,515,132 shares under the Company's Dividend Re-investment Scheme (DRIS). following which the Company's issued share capital consists of 355,997,862 ordinary shares with voting rights and 35,694,505 shares held in treasury.

Net assets

Net assets at 30 June 2025 comprised the following:

£000

% of net assets

Unquoted investments at fair value

159,047

55.2

Cash and money market funds

125,082

43.4

Other net assets

4,233

1.4

Net assets

288,362

100.0

Investments

The investment portfolio at 30 June 2025 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion

21,462

7.4%

Unbiased

14,554

12.5%

Vypr

10,938

16.3%

Xapien

8,726

19.3%

AutomatePro

8,403

22.2%

SharpCloud

8,193

25.1%

Summize

7,871

27.8%

DrDoctor

6,409

30.0%

Workbuzz

6,304

32.2%

Force24

6,259

34.4%

99,119

34.4%

Other investments

59,928

55.2%

Total investments

159,047

55.2%

 

Portfolio performance

Over the quarter to 30 June 2025, the aggregate unquoted portfolio valuation has increased by £2.7 million. Several portfolio companies are demonstrating strong underlying growth of revenues, which has driven positive revaluation uplifts across several assets. This has been balanced by downward movements in the valuations of Matillion, driven by foreign exchange movements; Outpost, due to sector-specific challenges; and Wooshii, where, as noted above, the trade and liabilities were realised shortly after the period end.

Fundraising

On 22 August 2025, the Company announced its intention to launch a new joint offer for subscription for the tax year 2025/26 later this year, alongside British Smaller Companies VCT2 plc (together the "BSC VCTs"). The current intention is for the BSC VCTs, in aggregate, to raise up to £60 million, with over-allotment facilities of up to a further £25 million in aggregate, before issue costs. Any election for the Company to make use of its over-allotment facility will be subject to the decisions of the individual boards of the BSC VCTs at the relevant time.

A prospectus with full details of the proposed Offer is expected to be published on or around 25 September, with applications expected to open one week following publication. Once published, the prospectus will be available from the BSC VCTs' website, www.bscfunds.com.

Outlook

The outlook for the UK economy over the coming months remains unclear. Inflation continues to run above expectations, with recent figures showing ongoing price increases despite limited growth. The Bank of England is likely to cut interest rates further, while the Government is managing tight fiscal conditions.

Internationally, economic uncertainty is being driven by trade disputes and unpredictable policy decisions. US-China tensions remain high, with tariffs altering global trade patterns. The global economy is still vulnerable to external shocks, including energy price swings and geopolitical instability in regions such as Ukraine and the Middle East.

Despite this environment, the Manager is still finding strong investment opportunities in fast-growing, technology-led businesses. Demand from existing portfolio companies also remains high, with many looking to accelerate their growth. These factors support a cautiously optimistic outlook for the Company.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

12 September 2025

For further information please contact:

Marcus Karia YFM Equity Partners Tel: 0113 244 1000

Alex Collins Panmure Liberum Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRFGPUGGBUPAGAG
Date   Source Headline
24th Oct 20249:00 amRNSUpdate on Offers
24th Oct 20249:00 amRNSUpdate on Offers
17th Oct 202412:45 pmRNSPublication of a Prospectus
17th Oct 202412:45 pmRNSPublication of a Prospectus
27th Sep 20247:33 amRNSTransaction in Own Shares
12th Sep 20247:00 amRNS1st Quarter Results
10th Sep 20244:30 pmRNSResult of AGM
10th Sep 20242:00 pmRNSUpdate on new combined offer for subscription
20th Aug 20247:00 amRNSStatement re NAV and Proposed Fundraising
20th Aug 20247:00 amRNSStatement re NAV and Proposed Fundraising
26th Jul 202410:42 amRNSPayment of dividend and allotment of shares
25th Jun 20247:00 amRNSTransaction in Own Shares
14th Jun 202412:30 pmRNSAnnual Financial Report
3rd Apr 20247:58 amRNSIssue of Equity and Close of Offers
26th Mar 202411:11 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNS3rd Quarter Results
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:23 amRNSIssue of Equity
18th Dec 20234:02 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
8th Dec 20239:47 amRNSPayment of Dividend and Issue of Equity
24th Nov 20237:00 amRNSHalf-year Report
26th Oct 20231:34 pmRNSDividend Declaration
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:20 amRNSTransaction in Own Shares and PDMR
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
14th Sep 202310:28 amRNSResult of AGM
14th Sep 202310:28 amRNSResult of General Meeting
13th Sep 20237:00 amRNS1st Quarter Results
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
28th Jul 202310:00 amRNSDirector/PDMR Shareholding
28th Jul 202310:00 amRNSPayment of Dividend and Issue of Equity
27th Jun 20237:45 amRNSTransaction in Own Shares
21st Jun 20231:00 pmRNSPublication of Circular
16th Jun 202312:00 pmRNSAnnual Financial Report
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:23 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:42 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.